U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced a new federal initiative to build a comprehensive autism data platform using Medicare and Medicaid records. Designed to study the causes of autism spectrum disorder (ASD), the platform will integrate claims data, electronic health records, and data from wearable health devices, according to the Department of Health and Human Services (HHS).
The National Institutes of Health (NIH) and the Centers for Medicare and Medicaid Services (CMS) will collaborate on the effort, which is part of a broader $50 million research initiative to investigate potential environmental and medical causes of autism. Kennedy stated the project aims to provide "honest answers families have waited far too long to hear," despite his controversial history promoting a debunked link between vaccines and autism.
HHS said the platform will help researchers analyze autism diagnoses, treatment outcomes, healthcare access disparities, and the financial impact on families. However, experts like Dr. Helen Tager-Flusberg of Boston University argue the focus does not directly address autism’s root causes. She also noted that an existing NIH autism database recently went offline without explanation, raising concerns about transparency.
The project has sparked privacy questions, as HHS has not confirmed whether the database will be anonymous or voluntary. Autism researcher Eric Rubenstein noted that Medicaid and Medicare data offer insights into health disparities but lack environmental exposure data, which Kennedy claims he will explore.
Autism rates have surged in recent years, with the CDC reporting 1 in 31 U.S. 8-year-olds diagnosed in 2022. While Kennedy aims to identify autism’s causes by September, scientists emphasize that autism likely stems from a complex mix of genetic and environmental factors. Critics warn against oversimplifying this ongoing scientific challenge.


Trump Signs “America First Arms Transfer Strategy” to Prioritize U.S. Weapons Sales
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns
Illinois Joins WHO Global Outbreak Network After U.S. Exit, Following California’s Lead
Trump Family Files $10 Billion Lawsuit Over IRS Tax Disclosure
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Trump Administration Expands Global Gag Rule, Restricting U.S. Foreign Aid to Diversity and Gender Programs
U.S. Justice Department Removes DHS Lawyer After Blunt Remarks in Minnesota Immigration Court
Federal Judge Blocks Trump Administration Move to End TPS for Haitian Immigrants
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 



